OBJECTIVE: We investigated the feasibility of serial dynamic contrast-enhanced computed tomography (DCE-CT) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receivinganti-angiogenic (sorafenib) and anti-EGFR (erlotinib) treatment, and correlated tumour blood flow (BF) with treatment outcome. METHODS: DCE-CTs were performed at baseline and 3 and 6 weeks after starting treatment. Tumour BF, calculated with the maximum slope method, and percentage change were measured in 23 patients (14 male; median age 59 years). Tumour BF was compared at baseline and weeks 3 and 6; the relation with RECIST/Crabb response and progression-free survival (PFS) was assessed. RESULTS:Mean tumour perfusion decreased from 39.2 ml/100 g/min at baseline to 15.1 ml/100 g/min at week 3 (p < 0.001) and 9.4 ml/100 g/min at week 6 (p < 0.001). Tumour perfusion was lower in RECIST and Crabb responders versus non-responders at week 3 (4.2 versus 17.7 ml/100 g/min, p = 0.03) and week 6 (0 versus 13.4 ml/100 g/min, p = 0.04). Patients with a decrease larger than the median at week 6 tended to have a longer PFS (7.1 versus 5.7 months, p = 0.06). CONCLUSION: Serial DCE-CTs are feasible in patients with NSCLC and demonstrated a significant decrease in tumour BF following sorafenib/erlotinib therapy. Early changes in tumour BF correlated with objective response and showed a trend towards longer PFS.
RCT Entities:
OBJECTIVE: We investigated the feasibility of serial dynamic contrast-enhanced computed tomography (DCE-CT) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving anti-angiogenic (sorafenib) and anti-EGFR (erlotinib) treatment, and correlated tumour blood flow (BF) with treatment outcome. METHODS: DCE-CTs were performed at baseline and 3 and 6 weeks after starting treatment. Tumour BF, calculated with the maximum slope method, and percentage change were measured in 23 patients (14 male; median age 59 years). Tumour BF was compared at baseline and weeks 3 and 6; the relation with RECIST/Crabb response and progression-free survival (PFS) was assessed. RESULTS: Mean tumour perfusion decreased from 39.2 ml/100 g/min at baseline to 15.1 ml/100 g/min at week 3 (p < 0.001) and 9.4 ml/100 g/min at week 6 (p < 0.001). Tumour perfusion was lower in RECIST and Crabb responders versus non-responders at week 3 (4.2 versus 17.7 ml/100 g/min, p = 0.03) and week 6 (0 versus 13.4 ml/100 g/min, p = 0.04). Patients with a decrease larger than the median at week 6 tended to have a longer PFS (7.1 versus 5.7 months, p = 0.06). CONCLUSION: Serial DCE-CTs are feasible in patients with NSCLC and demonstrated a significant decrease in tumour BF following sorafenib/erlotinib therapy. Early changes in tumour BF correlated with objective response and showed a trend towards longer PFS.
Authors: Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour Journal: N Engl J Med Date: 2005-07-14 Impact factor: 91.245
Authors: Quan Sing Ng; Vicky Goh; Ernst Klotz; Heinz Fichte; Michele I Saunders; Peter J Hoskin; Anwar R Padhani Journal: AJR Am J Roentgenol Date: 2006-10 Impact factor: 3.959
Authors: Quan-Sing Ng; Vicky Goh; Jessica Milner; Michael R Stratford; Lisa K Folkes; Gillian M Tozer; Michele I Saunders; Peter J Hoskin Journal: Lancet Oncol Date: 2007-02 Impact factor: 41.316
Authors: Frank Winkler; Sergey V Kozin; Ricky T Tong; Sung-Suk Chae; Michael F Booth; Igor Garkavtsev; Lei Xu; Daniel J Hicklin; Dai Fukumura; Emmanuelle di Tomaso; Lance L Munn; Rakesh K Jain Journal: Cancer Cell Date: 2004-12 Impact factor: 31.743
Authors: Martijn R Meijerink; Hester van Cruijsen; Klaas Hoekman; Matthijs Kater; Cors van Schaik; Jan Hein T M van Waesberghe; Giuseppe Giaccone; Radu A Manoliu Journal: Eur Radiol Date: 2006-10-27 Impact factor: 5.315
Authors: Michael I Koukourakis; Ioannis Mavanis; George Kouklakis; Michael Pitiakoudis; George Minopoulos; Costantinos Manolas; Costantinos Simopoulos Journal: Am J Clin Oncol Date: 2007-06 Impact factor: 2.339
Authors: F Kiessling; J Boese; C Corvinus; J R Ederle; I Zuna; S O Schoenberg; G Brix; A Schmähl; S Tuengerthal; F Herth; H U Kauczor; M Essig Journal: Eur Radiol Date: 2004-03-17 Impact factor: 5.315
Authors: James P Thomas; Rhoda Z Arzoomanian; Dona Alberti; Rebecca Marnocha; Fred Lee; Andreas Friedl; Kendra Tutsch; Amy Dresen; Peter Geiger; James Pluda; William Fogler; Joan H Schiller; George Wilding Journal: J Clin Oncol Date: 2003-01-15 Impact factor: 44.544
Authors: Mizuki Nishino; David M Jackman; Hiroto Hatabu; Pasi A Jänne; Bruce E Johnson; Annick D Van den Abbeele Journal: Acad Radiol Date: 2011-01-28 Impact factor: 3.173
Authors: Thomas Henzler; Jingyun Shi; Hashim Jafarov; Stefan O Schoenberg; Christian Manegold; Christian Fink; Gerald Schmid-Bindert Journal: Transl Lung Cancer Res Date: 2012-03
Authors: G Schmid-Bindert; Thomas Henzler; T Q Chu; M Meyer; J W Nance; U J Schoepf; D J Dinter; P Apfaltrer; R Krissak; C Manegold; S O Schoenberg; C Fink Journal: Eur Radiol Date: 2011-08-07 Impact factor: 5.315
Authors: James C Yao; Alexandria T Phan; Kenneth Hess; David Fogelman; Carmen Jacobs; Cecile Dagohoy; Colleen Leary; Keping Xie; Chaan S Ng Journal: Pancreas Date: 2015-03 Impact factor: 3.327
Authors: J de Castro; M Cobo; D Isla; J Puente; N Reguart; B Cabeza; A Gayete; M Sánchez; M I Torres; J Ferreirós Journal: Clin Transl Oncol Date: 2014-11-06 Impact factor: 3.405